RSS Feed Print
Clinical Trials 2019
Lane Simonian
Posted: Monday, May 20, 2019 9:57 AM
Joined: 12/12/2011
Posts: 4491


Michael Ellenbogen kindly sent me a report detailing ongoing drug clinical trials for Alzheimer's disease.  Here are parts of the summary:

New BIO Report: More Progress Needed in Innovation of Alzheimer’s Disease Therapeutics

Poor R&D Success Rates: Clinical development success for disease-modifying drug programs for Alzheimer’s has been difficult in late-stage trials, with no disease-modifying drugs moving beyond Phase III to FDA filing. Since 2008, a total of 87 clinical-stage disease-modifying programs have been suspended.

  • Growing & Diverse R&D Pipeline: There are 74 clinical-stage programs with disease-modifying potential in Alzheimer’s disease. The drug candidates in these programs are attempting to stop, prevent, or slow the progression of Alzheimer’s disease using 10 different strategies involving 30 distinct molecular targets. Small biotech companies account for more than three-fourths of these clinical programs.
The three main targets currently are amyloid, tau, and neuroinflammation.  By contrast there is only one pharmaceutical sponsored trial targeting oxidation.

Lane Simonian
Posted: Tuesday, May 21, 2019 10:21 AM
Joined: 12/12/2011
Posts: 4491


Here is a list of the ten strategies for treating Alzheimer's disease and the number of clinical trials for each:

Targeting the Amyloid Pathway (33)

Targeting the Tau Pathway (12)

Regeneration of Neurons (12)

Reversing Neuroinflammation (7)

Targeting Epigenetic Modification (3)

Targeting Metabolic Pathways (2)

Targeting Glucocorticoids (2)

Targeting Oxidative Stress (1)

Targeting Infectious Agents (1)

Targeting the Epichaperon (1)

Here is some information on preclinical trials:

Preclinical Pipeline To predict what may enter the clinical pipeline soon, we examined novel preclinical disease-modifying Alzheimer’s disease programs in the Biomedtracker databases and recently published literature. We found that 23 of the 102 preclinical programs listed had unique targets not currently in the clinic, indicating further advances may be on the horizon. The mechanistic strategies are quite varied within the 23 new targets, including caspases, different growth receptors, inflammation factors, kinases, and modified blood proteins that may restore or protect neuronal function. Sixteen of the preclinical programs had unknown mechanisms



HowDoYouDeal
Posted: Friday, May 31, 2019 9:04 AM
Joined: 2/17/2019
Posts: 42


You may want to have a look at non-drug therapies.

HowDoYouDeal
Posted: Tuesday, June 11, 2019 11:12 AM
Joined: 2/17/2019
Posts: 42


Vie Light announced a clinical trial on June 6, 2019

 

here are the results from the first trial, which had five people: